SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
SCHEDULE
13D
Under
the Securities Exchange Act of 1934
(Amendment
No. )*
|
EDESA BIOTECH, INC.
|
|
(Name of
Issuer)
|
|
Common Shares, no par value per
share
|
|
(Title of Class of Securities)
|
|
27966L108
|
|
(CUSIP
Number)
|
|
Kris Hanc
c/o Bennett Jones LLP
3400
One First Canadian Place, P.O. Box 130, Toronto, ON, M5X
1A4
(416)
777-7395
|
|
(Name, address and telephone number of
person
authorized to receive notices and
communications)
|
|
July 26, 2019
|
|
(Date of event which requires filing of this
statement)
|
If the filing
person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is
filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or
Rule 13d-1(g), check the following box .o
NOTE: Schedules
filed in paper format shall include a signed original and five
copies of the Schedule, including all exhibits. See Rule
13d-7(b) for other parties to whom copies are to be
sent.
————————————————
*The remainder of
this cover page shall be filled out for a reporting person’s
initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information
which would alter the disclosures provided in a prior cover
page.
The information
required on the remainder of this cover page shall not be deemed to
be “filed” for purpose of Section 18 of the Securities
Exchange Act of 1934 (“Act”) or otherwise subject to
the liabilities of that section of the Act but shall be subject to
all other provisions of the Act (however, see the
Notes)
|
CUSIP No.
27966L108
|
SCHEDULE
13D
|
Page 2 of 13 Pages
|
|
1
|
NAME OF REPORTING
PERSONS
10379085 Canada Inc.
|
|||
|
2
|
CHECK THE
APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)
☐
(b)
☐
|
|||
|
3
|
SEC USE
ONLY
|
|||
|
4
|
SOURCE OF
FUNDS
OO
|
|||
|
5
|
CHECK BOX IF
DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d)
or 2(e) ☐
|
|||
|
6
|
CITIZENSHIP OR
PLACE OF ORGANIZATION
Canada
|
|||
|
NUMBER
OF
|
7
|
SOLE VOTING
POWER
0
|
|
|
|
SHARES
BENEFICIALLY
|
8
|
SHARED VOTING
POWER
675,218
(1)
|
|
|
|
OWNED
BY
EACH
|
9
|
SOLE DISPOSITIVE
POWER
0
|
|
|
|
REPORTING
PERSON
WITH
|
10
|
SHARED DISPOSITIVE
POWER
675,218
(1)
|
|
|
|
11
|
AGGREGATE AMOUNT
BENEFICIALLY OWNED BY EACH REPORTING PERSON
675,218
(1)
|
|||
|
12
|
CHECK BOX IF THE
AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
☐
|
|||
|
13
|
PERCENT OF CLASS
REPRESENTED BY AMOUNT IN ROW (11)
9.0%
(Based on a total of 7,504,468 shares of the Issuer’s common
stock outstanding as of August 14, 2019)
|
|||
|
14
|
TYPE OF REPORTING
PERSON
CO
|
|||
(1)
These shares are
owned directly by 10379085 Canada
Inc., which is a wholly owned subsidiary of PCRI
Inc.
|
CUSIP No.
27966L108
|
SCHEDULE
13D
|
Page 3 of 13 Pages
|
|
1
|
NAME OF REPORTING
PERSONS
PCRI Inc.
|
|||
|
2
|
CHECK THE
APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)
☐
(b)
☐
|
|||
|
3
|
SEC USE
ONLY
|
|||
|
4
|
SOURCE OF
FUNDS
OO
|
|||
|
5
|
CHECK BOX IF
DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d)
or 2(e) ☐
|
|||
|
6
|
CITIZENSHIP OR
PLACE OF ORGANIZATION
Canada
|
|||
|
NUMBER
OF
|
7
|
SOLE VOTING
POWER
0
|
|
|
|
SHARES
BENEFICIALLY
|
8
|
SHARED VOTING
POWER
675,218
(1)
|
|
|
|
OWNED
BY
EACH
|
9
|
SOLE DISPOSITIVE
POWER
0
|
|
|
|
REPORTING
PERSON
WITH
|
10
|
SHARED DISPOSITIVE
POWER
675,218
(1)
|
|
|
|
11
|
AGGREGATE AMOUNT
BENEFICIALLY OWNED BY EACH REPORTING PERSON
675,218
(1)
|
|||
|
12
|
CHECK BOX IF THE
AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
☐
|
|||
|
13
|
PERCENT OF CLASS
REPRESENTED BY AMOUNT IN ROW (11)
9.0%
(Based on a total of 7,504,468 shares of the Issuer’s common
stock outstanding as of August 14, 2019)
|
|||
|
14
|
TYPE OF REPORTING
PERSON
CO
|
|||
(1)
These shares are
owned directly by 10379085 Canada
Inc., which is a wholly owned subsidiary of PCRI
Inc.
|
CUSIP No.
27966L108
|
SCHEDULE
13D
|
Page 4 of 13 Pages
|
|
1
|
NAME OF REPORTING
PERSONS
Morris
Goodman
|
|||
|
2
|
CHECK THE
APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)
☐
(b)
☐
|
|||
|
3
|
SEC USE
ONLY
|
|||
|
4
|
SOURCE OF
FUNDS
OO
|
|||
|
5
|
CHECK BOX IF
DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d)
or 2(e) ☐
|
|||
|
6
|
CITIZENSHIP OR
PLACE OF ORGANIZATION
Canada
|
|||
|
NUMBER
OF
|
7
|
SOLE VOTING
POWER
0
|
|
|
|
SHARES
BENEFICIALLY
|
8
|
SHARED VOTING
POWER
675,218
(1)
|
|
|
|
OWNED
BY
EACH
|
9
|
SOLE DISPOSITIVE
POWER
0
|
|
|
|
REPORTING
PERSON
WITH
|
10
|
SHARED DISPOSITIVE
POWER
675,218
(1)
|
|
|
|
11
|
AGGREGATE AMOUNT
BENEFICIALLY OWNED BY EACH REPORTING PERSON
675,218
(1)
|
|||
|
12
|
CHECK BOX IF THE
AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
☐
|
|||
|
13
|
PERCENT OF CLASS
REPRESENTED BY AMOUNT IN ROW (11)
9.0%
(Based on a total of 7,504,468 shares of the Issuer’s common
stock outstanding as of August 14, 2019)
|
|||
|
14
|
TYPE OF REPORTING
PERSON
IN
|
|||
(1)
These shares are
owned directly by 10379085 Canada
Inc., which is a wholly owned subsidiary of PCRI
Inc.
|
CUSIP No.
27966L108
|
SCHEDULE
13D
|
Page 5 of 13 Pages
|
|
1
|
NAME OF REPORTING
PERSONS
David Goodman
|
|||
|
2
|
CHECK THE
APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)
☐
(b)
☐
|
|||
|
3
|
SEC USE
ONLY
|
|||
|
4
|
SOURCE OF
FUNDS
OO
|
|||
|
5
|
CHECK BOX IF
DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d)
or 2(e) ☐
|
|||
|
6
|
CITIZENSHIP OR
PLACE OF ORGANIZATION
Canada
|
|||
|
NUMBER
OF
|
7
|
SOLE VOTING
POWER
0
|
|
|
|
SHARES
BENEFICIALLY
|
8
|
SHARED VOTING
POWER
675,218
(1)
|
|
|
|
OWNED
BY
EACH
|
9
|
SOLE DISPOSITIVE
POWER
0
|
|
|
|
REPORTING
PERSON
WITH
|
10
|
SHARED DISPOSITIVE
POWER
675,218
(1)
|
|
|
|
11
|
AGGREGATE AMOUNT
BENEFICIALLY OWNED BY EACH REPORTING PERSON
675,218
(1)
|
|||
|
12
|
CHECK BOX IF THE
AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
☐
|
|||
|
13
|
PERCENT OF CLASS
REPRESENTED BY AMOUNT IN ROW (11)
9.0%
(Based on a total of 7,504,468 shares of the Issuer’s common
stock outstanding as of August 14, 2019)
|
|||
|
14
|
TYPE OF REPORTING
PERSON
IN
|
|||
(1)
These shares are
owned directly by 10379085 Canada
Inc., which is a wholly owned subsidiary of PCRI
Inc.
|
CUSIP No.
27966L108
|
SCHEDULE
13D
|
Page 6 of 13 Pages
|
|
1
|
NAME OF REPORTING
PERSONS
Gregory Orleski
|
|||
|
2
|
CHECK THE
APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)
☐
(b)
☐
|
|||
|
3
|
SEC USE
ONLY
|
|||
|
4
|
SOURCE OF
FUNDS
OO
|
|||
|
5
|
CHECK BOX IF
DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d)
or 2(e) ☐
|
|||
|
6
|
CITIZENSHIP OR
PLACE OF ORGANIZATION
Canada
|
|||
|
NUMBER
OF
|
7
|
SOLE VOTING
POWER
0
|
|
|
|
SHARES
BENEFICIALLY
|
8
|
SHARED VOTING
POWER
675,218
(1)
|
|
|
|
OWNED
BY
EACH
|
9
|
SOLE DISPOSITIVE
POWER
0
|
|
|
|
REPORTING
PERSON
WITH
|
10
|
SHARED DISPOSITIVE
POWER
675,218
(1)
|
|
|
|
11
|
AGGREGATE AMOUNT
BENEFICIALLY OWNED BY EACH REPORTING PERSON
675,218
(1)
|
|||
|
12
|
CHECK BOX IF THE
AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
☐
|
|||
|
13
|
PERCENT OF CLASS
REPRESENTED BY AMOUNT IN ROW (11)
9.0%
(Based on a total of 7,504,468 shares of the Issuer’s common
stock outstanding as of August 14, 2019)
|
|||
|
14
|
TYPE OF REPORTING
PERSON
IN
|
|||
(1)
These shares are
owned directly by 10379085 Canada
Inc., which is a wholly owned subsidiary of PCRI
Inc.
|
CUSIP No.
27966L108
|
SCHEDULE
13D
|
Page 7 of 13 Pages
|
|
1
|
NAME OF REPORTING
PERSONS
Sonia
Girolamo
|
|||
|
2
|
CHECK THE
APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)
☐
(b)
☐
|
|||
|
3
|
SEC USE
ONLY
|
|||
|
4
|
SOURCE OF
FUNDS
OO
|
|||
|
5
|
CHECK BOX IF
DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d)
or 2(e) ☐
|
|||
|
6
|
CITIZENSHIP OR
PLACE OF ORGANIZATION
Canada
|
|||
|
NUMBER
OF
|
7
|
SOLE VOTING
POWER
0
|
|
|
|
SHARES
BENEFICIALLY
|
8
|
SHARED VOTING
POWER
675,218
(1)
|
|
|
|
OWNED
BY
EACH
|
9
|
SOLE DISPOSITIVE
POWER
0
|
|
|
|
REPORTING
PERSON
WITH
|
10
|
SHARED DISPOSITIVE
POWER
675,218
(1)
|
|
|
|
11
|
AGGREGATE AMOUNT
BENEFICIALLY OWNED BY EACH REPORTING PERSON
675,218
(1)
|
|||
|
12
|
CHECK BOX IF THE
AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
☐
|
|||
|
13
|
PERCENT OF CLASS
REPRESENTED BY AMOUNT IN ROW (11)
9.0%
(Based on a total of 7,504,468 shares of the Issuer’s common
stock outstanding as of August 14, 2019)
|
|||
|
14
|
TYPE OF REPORTING
PERSON
IN
|
|||
(1)
These shares are
owned directly by 10379085 Canada
Inc., which is a wholly owned subsidiary of PCRI
Inc.
|
CUSIP No.
27966L108
|
SCHEDULE
13D
|
Page 8 of 13 Pages
|
|
1
|
NAME OF REPORTING
PERSONS
Jean-Guy Goulet
|
|||
|
2
|
CHECK THE
APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)
☐
(b)
☐
|
|||
|
3
|
SEC USE
ONLY
|
|||
|
4
|
SOURCE OF
FUNDS
OO
|
|||
|
5
|
CHECK BOX IF
DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d)
or 2(e) ☐
|
|||
|
6
|
CITIZENSHIP OR
PLACE OF ORGANIZATION
Canada
|
|||
|
NUMBER
OF
|
7
|
SOLE VOTING
POWER
0
|
|
|
|
SHARES
BENEFICIALLY
|
8
|
SHARED VOTING
POWER
675,218
(1)
|
|
|
|
OWNED
BY
EACH
|
9
|
SOLE DISPOSITIVE
POWER
0
|
|
|
|
REPORTING
PERSON
WITH
|
10
|
SHARED DISPOSITIVE
POWER
675,218
(1)
|
|
|
|
11
|
AGGREGATE AMOUNT
BENEFICIALLY OWNED BY EACH REPORTING PERSON
675,218
(1)
|
|||
|
12
|
CHECK BOX IF THE
AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
☐
|
|||
|
13
|
PERCENT OF CLASS
REPRESENTED BY AMOUNT IN ROW (11)
9.0%
(Based on a total of 7,504,468 shares of the Issuer’s common
stock outstanding as of August 14, 2019)
|
|||
|
14
|
TYPE OF REPORTING
PERSON
IN
|
|||
(1)
These shares are
owned directly by 10379085 Canada
Inc., which is a wholly owned subsidiary of PCRI
Inc.
This
Amendment No. 1 (“Amendment No. 1”) amends
and supplements the statement on Schedule 13D jointly filed by
(i)
10379085 Canada Inc., (ii) PCRI Inc, (iii) Morris Goodman, an
individual, (iv) David Goodman, an individual, (v) Gregory Orleski,
an individual, (vi) Sonia Girolamo, an individual, and (vii)
Jean-Guy Goulet, an individual (collectively, the “Reporting
Persons”) on June 25, 2019 (as so amended and
supplemented, the “Schedule 13D”), with respect to the
common shares, no par value per share (the “Common
Shares”) of Edesa Biotech, Inc., a British Columbia
corporation, formerly known as
“Stellar Biotechnologies, Inc.” (the
“Company” or the “Issuer”). Except as
expressly amended by this Amendment No. 1, the Schedule 13D
remains in full force and effect.
The
purpose of this Amendment No. 1 is to report an increase in
the Reporting Persons’ beneficial ownership of Common Shares
as a result of the issuance of Common Shares on July 26, 2019
pursuant to the post-closing adjustment contemplated by that
certain Share Exchange Agreement, dated as of March 7, 2019, by and
among the Company, Edesa Biotech Inc. (“Edesa”) and the
shareholders of Edesa (the “Exchange Agreement”), as
described in this Amendment No. 1.
Item
1.
Security
and Issuer.
This Schedule 13D
relates to the Common Shares of the Company, which has its
principal executive offices at 100 Spy Court, Markham, Ontario,
Canada L3R 5H6.
Item
2.
Identity
and Background.
This Schedule 13D is
filed by the Reporting Persons. 10379085 Canada Inc. is
a wholly owned subsidiary of PCRI Inc.
The principal address of
the Reporting Persons is 100-6111 vie.
Royalmount Ave., Montreal, Quebec, Canada, H4P
2T4.
Both 10379085 Canada
Inc. and PCRI are holding corporations. Morris Goodman, David
Goodman, Gregory Orleski and Sonia Girolamo are each officers and
directors of PCRI Inc. and 10379085 Canada Inc. and Jean-Guy
Goulet is a director of 10379085 Canada
Inc. The foregoing
individuals collectively make investment decisions with respect to
the securities held by 10379085 Canada
Inc.
During
the last five years, none of the Reporting Persons have been
convicted in a criminal proceeding (excluding traffic violations
and similar misdemeanors) or been a party to a civil proceeding of
a judicial or administrative body of competent jurisdiction and as
a result of such proceeding, was or is subject to a judgment,
decree or final order enjoining future violations of, or
prohibiting or mandating activities subject to, federal or state
securities laws or finding any violation with respect to such
laws.
Item
3.
Source
or Amount of Funds or Other Consideration.
On June 7, 2019, the Company completed its business combination
with Edesa in accordance with the terms of the Exchange Agreement
(the “Exchange”), pursuant to which 10379085 Canada
Inc. received 638,372 common shares in exchange for all of its
capital stock of Edesa.
On July 26, 2019, an additional 36,846 Common Shares were issued to
10379085 Canada Inc. pursuant to the post-closing adjustment
contemplated by the Exchange Agreement.
The
foregoing description of the Exchange Agreement does not purport to
be complete and is qualified in its entirety by reference to such
agreement, which is attached hereto as Exhibit 2 and incorporated
herein by reference.
Item
4.
Purpose
of the Transaction.
Reference is made
to the disclosure set forth under Item 3 of this Schedule 13D,
which disclosure is incorporated herein by reference.
The Reporting Persons intend to review their investment in the
Issuer on a continuing basis and, depending on various factors,
including, without limitation, the Issuer’s financial
position, the price of the Common Shares, conditions in the
securities markets and general economic and industry conditions,
the Reporting Persons may, in the future, take such actions with
respect to their shares of the Issuer’s capital stock as they
deem appropriate, including, without limitation: purchasing
additional Common Shares; selling Common Shares; taking any action
to change the composition of the Issuer’s board of directors;
taking any other action with respect to the Issuer or any of its
securities in any manner permitted by law or changing their
intention with respect to any and all matters referred to in
paragraphs (a) through (j) below in this
Item 4.
Except as otherwise described in this Schedule, none of the
Reporting Persons currently has any plans or proposals that relate
to or would result in: (a) the acquisition by any person of
additional securities of the Issuer, or the disposition of
securities of the Issuer; (b) an extraordinary corporate
transaction, such as a merger, reorganization or liquidation,
involving the Issuer or any of its subsidiaries; (c) a sale or
transfer of a material amount of assets of the Issuer or any of its
subsidiaries; (d) any change in the present board of directors
or management of the Issuer, including any plans or proposals to
change the number or term of directors or to fill any existing
vacancies on the board; (e) any material change in the present
capitalization or dividend policy of the Issuer; (f) any other
material change in the Issuer’s business or corporate
structure; (g) any changes in the Issuer’s charter or
bylaws or other actions which may impede the acquisition of control
of the Issuer by any person; (h) causing a class of securities
of the Issuer to be delisted from a national securities exchange or
to cease to be authorized to be quoted in an interdealer quotation
system of a registered national securities association;
(i) causing a class of equity securities of the Issuer to
become eligible for termination of registration pursuant to
Section 12(g)(4) of the Securities Exchange Act of 1934, as
amended; or (j) any action similar to any of those enumerated
above.
Item
5.
Interest
in Securities of the Issuer.
(a)-(b)
Number of Common Shares beneficially owned:
|
10379085 Canada Inc.
|
675,218 shares
|
|
PCRI, Inc.
|
675,218 shares
|
|
Morris Goodman
|
675,218 shares
|
|
David Goodman
|
675,218 shares
|
|
Gregory Orleski
|
675,218 shares
|
|
Sonia Girolamo
|
675,218 shares
|
|
Jean-Guy Goulet
|
675,218 shares
|
Percent of
class:
|
|
|
|
10379085 Canada Inc.
|
9.0%
|
|
PCRI, Inc.
|
9.0%
|
|
Morris Goodman
|
9.0%
|
|
David Goodman
|
9.0%
|
|
Gregory Orleski
|
9.0%
|
|
Sonia Girolamo
|
9.0%
|
|
Jean-Guy Goulet
|
9.0%
|
The percentage ownership was calculated based on 7,504,468
Common Shares outstanding as of August 14, 2019.
Number of shares as to which such person has:
(i)
Sole power to vote or to direct the vote:
|
10379085 Canada Inc.
|
0 shares
|
|
PCRI, Inc.
|
0 shares
|
|
Morris Goodman
|
0 shares
|
|
David Goodman
|
0 shares
|
|
Gregory Orleski
|
0 shares
|
|
Sonia Girolamo
|
0 shares
|
|
Jean-Guy Goulet
|
0 shares
|
(ii) Shared
power to vote or to direct the vote:
|
10379085 Canada Inc.
|
675,218 shares
|
|
PCRI, Inc.
|
675,218 shares
|
|
Morris Goodman
|
675,218 shares
|
|
David Goodman
|
675,218 shares
|
|
Gregory Orleski
|
675,218 shares
|
|
Sonia Girolamo
|
675,218 shares
|
|
Jean-Guy Goulet
|
675,218 shares
|
(iii) Sole power
to dispose or to direct the disposition of:
|
10379085 Canada Inc.
|
0 shares
|
|
PCRI, Inc.
|
0 shares
|
|
Morris Goodman
|
0 shares
|
|
David Goodman
|
0 shares
|
|
Gregory Orleski
|
0 shares
|
|
Sonia Girolamo
|
0 shares
|
|
Jean-Guy Goulet
|
0 shares
|
(iv) Shared
power to dispose or to direct the disposition
of:
|
10379085 Canada Inc.
|
675,218 shares
|
|
PCRI, Inc.
|
675,218 shares
|
|
Morris Goodman
|
675,218 shares
|
|
David Goodman
|
675,218 shares
|
|
Gregory Orleski
|
675,218 shares
|
|
Sonia Girolamo
|
675,218 shares
|
|
Jean-Guy Goulet
|
675,218 shares
|
(c)
Except as set forth in this Schedule 13D, the Reporting Persons
have not effected any transactions with respect to the Common
Shares of the Issuer during the past 60 days.
(d)-(e)
Not applicable.
Item
6.
Contracts,
Arrangements, Understandings or Relationships With Respect to
Securities of the Issuer.
Reference is made
to the disclosure set forth under Items 3 of this Schedule 13D,
which disclosure is incorporated herein by
reference.
Item
7.
Material
to be filed as Exhibits.
Exhibit No.
Description
Joint Filing Agreement,
dated as of September 9, 2019 by and among by (i)
10379085 Canada Inc., (ii) PCRI Inc, (iii) Morris Goodman, an
individual, (iv) David Goodman, an individual, (v) Gregory Orleski,
an individual, (vi) Sonia Girolamo, an individual, and (vii)
Jean-Guy Goulet, an individual.
2.
Share Exchange
Agreement, dated as of March 7, 2019, by and between Stellar
Biotechnologies, Inc., Edesa Biotech Inc. and the Edesa
Shareholders (incorporated by reference to Exhibit 2.1 of the
Issuer’s Current Report on Form 8-K filed with the Securities
and Exchange Commission on March 8, 2019).
SIGNATURES
After reasonable
inquiry and to the best of my knowledge and belief, I certify that
the information set forth in this statement is true, complete and
correct.
|
|
10379085 Canada
Inc.
|
|
|
|
|
|
|
|
|
Dated: September 9,
2019
|
By:
|
/s/ GREGORY ORLESKI
|
|
|
|
|
GREGORY
ORLESKI
|
|
|
|
|
|
|
|
|
PCRI
INC.
|
|
|
|
|
|
|
|
|
Dated: September 9,
2019
|
By:
|
/s/ GREGORY
ORLESKI
|
|
|
|
|
GREGORY ORLESKI
|
|
|
|
|
|
|
|
|
By:
|
/s/ MORRIS
GOODMAN
|
|
|
|
|
MORRIS
GOODMAN
|
|
|
|
|
|
|
|
|
By:
|
/s/ DAVID
GOODMAN
|
|
|
|
|
DAVID GOODMAN
|
|
|
|
|
|
|
|
|
By:
|
/s/ GREGORY
ORLESKI
|
|
|
|
|
GREGORY
ORLESKI
|
|
|
|
|
|
|
|
|
By:
|
/s/ SONIA
GIROLAMO
|
|
|
|
|
SONIA
GIROLAMO
|
|
|
|
|
|
|
|
|
By:
|
/s/ JEAN-GUY
GOULET
|
|
|
|
|
JEAN-GUY
GOULET
|
|
|
|
|
|
|
Exhibit 1
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1)
The undersigned acknowledge and agree that the foregoing statement
on Schedule 13D is filed on behalf of each of the undersigned and
that all subsequent amendments to this statement on Schedule 13D
shall be filed on behalf of each of the undersigned without the
necessity of filing additional joint filing statements. The
undersigned acknowledge that each shall be responsible for the
timely filing of such amendments, and for the completeness and
accuracy of the information concerning him, her or it contained
herein, but shall not be responsible for the completeness and
accuracy of the information concerning the other entities or
persons, except to the extent that he, she or it knows or has
reason to believe that such information is inaccurate.
|
|
10379085 Canada
Inc.
|
|
|
|
|
|
|
|
|
Dated: September 9,
2019
|
By:
|
/s/ GREGORY ORLESKI
|
|
|
|
|
GREGORY
ORLESKI
|
|
|
|
|
|
|
|
|
PCRI
INC.
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ GREGORY
ORLESKI
|
|
|
|
|
GREGORY ORLESKI
|
|
|
|
|
|
|
|
|
By:
|
/s/ MORRIS
GOODMAN
|
|
|
|
|
MORRIS
GOODMAN
|
|
|
|
|
|
|
|
|
By:
|
/s/ DAVID
GOODMAN
|
|
|
|
|
DAVID GOODMAN
|
|
|
|
|
|
|
|
|
By:
|
/s/ GREGORY
ORLESKI
|
|
|
|
|
GREGORY
ORLESKI
|
|
|
|
|
|
|
|
|
By:
|
/s/ SONIA
GIROLAMO
|
|
|
|
|
SONIA
GIROLAMO
|
|
|
|
|
|
|
|
|
By:
|
/s/ JEAN-GUY
GOULET
|
|
|
|
|
JEAN-GUY
GOULET
|
|
|
|
|
|
|